All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What should be done for elderly patients with primary central nervous system lymphoma?

Jun 6, 2019
Share:

At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Matthias Holdhoff, Johns Hopkins University, discusses the treatment options for elderly patients with primary central nervous system (CNS) lymphoma.

Dr. Holdhoff explains how over 50% of patients who are diagnosed are 60 years or older. The outcomes for patients who are treated for primary central nervous lymphomas has significantly improved over the last 4 decades, partly due to more aggressive therapies that have been tolerated reasonably well. Dr. Holdhoff then goes on to explain how the term elderly has evolved over time, as patients tend to live longer and comorbidities can be better managed, as well as how giving therapy with high dose methotrexate can very well be tolerated in old or very old patients.

What should be done for elderly patients with primary central nervous system lymphoma?